Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Millan

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2007
Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activityB Chanrion, C Mannoury la Cour, F Bertaso, et al.
European Journal of Pharmacology|January 5, 1993
S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectivelyM J Millan, J M Rivet, H Canton, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 28, 1998
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptorsA Newman-Tancredi, J P Nicolas, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2000
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626M J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivoM J Millan, J M Rivet, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1994
Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonistsM J Millan, H Canton, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidineM J Millan, F Lejeune, A Gobert, et al.
Synapse (New York, N.Y.)|May 20, 2000
Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the ratA Gobert, J M Rivet, F Lejeune, et al.
The European Journal of Neuroscience|April 13, 2000
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopramM J Millan, A Gobert, J M Rivet, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agentsM J Millan, M Brocco, J M Rivet, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2007
Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activityB Chanrion, C Mannoury la Cour, F Bertaso, et al.
European Journal of Pharmacology|January 5, 1993
S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectivelyM J Millan, J M Rivet, H Canton, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 28, 1998
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptorsA Newman-Tancredi, J P Nicolas, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2000
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626M J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivoM J Millan, J M Rivet, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1994
Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonistsM J Millan, H Canton, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidineM J Millan, F Lejeune, A Gobert, et al.
Synapse (New York, N.Y.)|May 20, 2000
Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the ratA Gobert, J M Rivet, F Lejeune, et al.
The European Journal of Neuroscience|April 13, 2000
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopramM J Millan, A Gobert, J M Rivet, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agentsM J Millan, M Brocco, J M Rivet, et al.
Pageof 23